Highlights Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Market Closed - Nasdaq Other stock markets 01:30:00 08/05/2024 am IST			5-day change	1st Jan Change
25 ^USD	-0.64%		+10.52%	-18.30%

03/05	Arrowhead Nets $50 Milestone Payment from Royalty Pharma After Completion of Enrollment in Trial of Cardiovascular Drug	MT
24/04	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Arrowhead Nets $50 Milestone Payment from Royalty Pharma After Completion of Enrollment in Trial of Cardiovascular Drug	03/05	MT
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease	24/04	CI
Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo	07/04	CI
Arrowhead Pharmaceuticals, Inc. Initiates Expanded Access Program for Plozasiran	25/03	CI
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy	08/03	CI
Arrowhead Pharmaceuticals Fiscal Q1 Loss Widens, Revenue Declines	07/02	MT
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	07/02	CI
Arrowhead Pharmaceuticals' Fiscal 2023 Net Loss Widens, Revenue Falls	30/11	MT
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	30/11	CI
Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy	28/11	CI
Arrowhead Pharmaceuticals Inc. Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023	13/11	CI
Arrowhead Pharmaceuticals' Fiscal Q3 Loss Widens, Revenue Drops	08/23/08	MT
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	08/23/08	CI
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate A Phase 1 Study of Aro-Sod1	27/23/27	CI
Arrowhead Pharmaceuticals Fiscal Q2 Earnings Rise, Revenue Declines	03/23/03	MT
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	03/23/03	CI
Arrowhead Pharmaceuticals Inc. Announces First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead	04/23/04	CI
Arrowhead Pharmaceuticals Receives $30 Million Milestone Payment from GSK for Phase 2b Trial of GSK4532990	03/23/03	MT
Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases	28/23/28	CI
Arrowhead Pharmaceuticals, Inc. Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results	15/23/15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Highlights

Filters